Last 12 months
Inside the activity.
0 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 16, 2018 Filed Apr 16, 2018 21:57 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
SaleCommon Stock | 5,034 | $44.88 | $225,925.42 |
DisclosureSEC source: 0001179110-18-005696 · edgar.xml · nonDerivative · entry 4 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,396 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F3 · price: The price reported in Column 4 is the average price of $44.8799. The shares sold between $44.85 to 45.00.The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 16, 2018 Filed Apr 16, 2018 21:57 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
SaleCommon Stock | 6,250 | $45.01 | $281,322.50 |
DisclosureSEC source: 0001179110-18-005696 · edgar.xml · nonDerivative · entry 3 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,430 F2 · price: The price reported in Column 4 is the exact price of $45.0116. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 16, 2018 Filed Apr 16, 2018 21:57 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
Exercise / conversionCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-005696 · edgar.xml · nonDerivative · entry 2 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. Read SEC document |
| April 12, 2018 Filed Apr 12, 2018 21:59 UTC |
Kuipers Peter J.Executive V P& CFO
|
Exercise / conversionStock Options NQ (right to Buy) · Derivative | 724 | $0.00 Strike: $27.70 | $0.00 |
DisclosureSEC source: 0001179110-18-005612 · edgar.xml · derivative · entry 4 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 724 shares Expires 2026-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2018 Filed Apr 12, 2018 21:59 UTC |
Kuipers Peter J.Executive V P& CFO
|
SaleCommon Stock | 724 | $46.00 | $33,304.00 |
DisclosureSEC source: 0001179110-18-005612 · edgar.xml · nonDerivative · entry 3 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,970 F2 · shares: The price reported in Column 4 is the exact price of $46.00. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · price: The price reported in Column 4 is the exact price of $46.00. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 12, 2018 Filed Apr 12, 2018 21:59 UTC |
Kuipers Peter J.Executive V P& CFO
|
Exercise / conversionCommon Stock | 724 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-005612 · edgar.xml · nonDerivative · entry 2 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,694 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 20:05 UTC |
SPEARS JOSEPH BRIANChief Accounting Officer & VP
|
Tax withholdingCommon Stock | 206 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-004442 · edgar.xml · nonDerivative · entry 2 SPEARS JOSEPH BRIAN · CIK 0001729964 · Chief Accounting Officer & VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,882 F2 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 20:04 UTC |
PETERSMEYER GARY SDirector
|
SaleCommon Stock | 575 | $44.43 | $25,544.38 |
DisclosureSEC source: 0001179110-18-004441 · edgar.xml · nonDerivative · entry 2 PETERSMEYER GARY S · CIK 0001206986 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,685 F1 · price: The price reported in Column 4 is the Exact price of $44.4250 for all the shares. sold The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 09, 2018 Filed Mar 27, 2019 18:46 UTC |
Kuipers Peter J.Executive V P& CFO
|
SaleCommon Stock | 1,044 | $44.34 | $46,288.87 |
DisclosureSEC source: 0001179110-19-004322 · edgar.xml · nonDerivative · entry 2 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,829 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. This Form 4 is being filed late due to an inadvertent administrative error. F1 · price: The price reported in Column 4 is the exact price of $44.3380. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 23:20 UTC |
Ngo Nhat HEVP, Marketing, S & B D
|
Tax withholdingCommon Stock | 909 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-003805 · edgar.xml · nonDerivative · entry 2 Ngo Nhat H · CIK 0001305020 · EVP, Marketing, S & B D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,030 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 23:20 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
SaleCommon Stock | 8,186 | $44.21 | $361,938.26 |
DisclosureSEC source: 0001179110-18-003804 · edgar.xml · nonDerivative · entry 5 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,323 F5 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F4 · price: The price reported in Column 4 is the average price of $44.2143. The shares sold in between $43.75.50 to $44.70. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 23:20 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
Tax withholdingCommon Stock | 4,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-003804 · edgar.xml · nonDerivative · entry 4 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,509 F3 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 23:19 UTC |
DREW J CHRISTOPHERPresident, North American A&A
|
Tax withholdingCommon Stock | 1,298 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-003802 · edgar.xml · nonDerivative · entry 3 DREW J CHRISTOPHER · CIK 0001271482 · President, North American A&A 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,539 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 23:20 UTC |
Seim Robin GenePresident, Global A & M A
|
Tax withholdingCommon Stock | 1,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-003803 · edgar.xml · nonDerivative · entry 2 Seim Robin Gene · CIK 0001351911 · President, Global A & M A 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,121 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 23:19 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
Tax withholdingCommon Stock | 914 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-003801 · edgar.xml · nonDerivative · entry 2 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,430 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 23:19 UTC |
Kuipers Peter J.Executive V P& CFO
|
Tax withholdingCommon Stock | 1,266 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-003800 · edgar.xml · nonDerivative · entry 2 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,970 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 23:18 UTC |
Taborga Jorge R.EVP, Global R & D
|
Tax withholdingCommon Stock | 972 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-003799 · edgar.xml · nonDerivative · entry 2 Taborga Jorge R. · CIK 0001571822 · EVP, Global R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,640 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| February 12, 2018 Filed Feb 12, 2018 22:50 UTC |
Judson James TDirector
|
Exercise / conversionStock Options NQ (Right to Buy) · Derivative | 17,443 | $0.00 Strike: $9.25 | $0.00 |
DisclosureSEC source: 0001179110-18-001971 · edgar.xml · derivative · entry 3 Judson James T · CIK 0001326789 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,443 shares Expires 2019-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2018 Filed Feb 12, 2018 22:50 UTC |
Judson James TDirector
|
Exercise / conversionCommon Stock | 17,443 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-001971 · edgar.xml · nonDerivative · entry 2 Judson James T · CIK 0001326789 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Stock option exercised for Cash. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:47 UTC |
Ngo Nhat HEVP, Marketing, S & B D
|
GrantStock Option (Right to Buy) · Derivative | 36,096 | $0.00 Strike: $44.25 | $0.00 |
DisclosureSEC source: 0001179110-18-001774 · edgar.xml · derivative · entry 4 Ngo Nhat H · CIK 0001305020 · EVP, Marketing, S & B D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,096 Underlying: Common Stock · 36,096 shares Expires 2028-02-06 F1 · shares: Shares shall vest ratably over 48 month period, with a year cliff. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:47 UTC |
Ngo Nhat HEVP, Marketing, S & B D
|
GrantCommon Stock | 9,224 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-001774 · edgar.xml · nonDerivative · entry 3 Ngo Nhat H · CIK 0001305020 · EVP, Marketing, S & B D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,939 F3 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2019 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2019 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:47 UTC |
Ngo Nhat HEVP, Marketing, S & B D
|
GrantCommon Stock | 8,136 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-001774 · edgar.xml · nonDerivative · entry 2 Ngo Nhat H · CIK 0001305020 · EVP, Marketing, S & B D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,715 F2 · shares: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:47 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 161,678 | $0.00 Strike: $44.25 | $0.00 |
DisclosureSEC source: 0001179110-18-001773 · edgar.xml · derivative · entry 5 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,678 Underlying: Common Stock · 161,678 shares Expires 2028-02-06 F3 · shares: Shares shall vest ratably over 48 month period, with a year cliff. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:47 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
GrantCommon Stock | 55,088 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-001773 · edgar.xml · nonDerivative · entry 4 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,206 F4 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2019 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2019 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:47 UTC |
DREW J CHRISTOPHERPresident, North American A&A
|
GrantStock Option (Right to Buy) · Derivative | 30,080 | $0.00 Strike: $44.25 | $0.00 |
DisclosureSEC source: 0001179110-18-001772 · edgar.xml · derivative · entry 5 DREW J CHRISTOPHER · CIK 0001271482 · President, North American A&A 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,080 Underlying: Common Stock · 30,080 shares Expires 2028-02-06 F2 · shares: Shares shall vest ratably over 48 month period, with a year cliff. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:47 UTC |
DREW J CHRISTOPHERPresident, North American A&A
|
GrantCommon Stock | 7,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-001772 · edgar.xml · nonDerivative · entry 4 DREW J CHRISTOPHER · CIK 0001271482 · President, North American A&A 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,837 F3 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2019 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2019 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:47 UTC |
DREW J CHRISTOPHERPresident, North American A&A
|
GrantCommon Stock | 6,780 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-001772 · edgar.xml · nonDerivative · entry 3 DREW J CHRISTOPHER · CIK 0001271482 · President, North American A&A 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,150 F1 · shares: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:46 UTC |
Seim Robin GenePresident, Global A & M A
|
GrantStock Option (Right to Buy) · Derivative | 51,136 | $0.00 Strike: $44.25 | $0.00 |
DisclosureSEC source: 0001179110-18-001771 · edgar.xml · derivative · entry 4 Seim Robin Gene · CIK 0001351911 · President, Global A & M A 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,136 Underlying: Common Stock · 51,136 shares Expires 2028-02-06 F2 · shares: Shares shall vest ratably over 48 month period, with a year cliff. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:46 UTC |
Seim Robin GenePresident, Global A & M A
|
GrantCommon Stock | 13,067 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-001771 · edgar.xml · nonDerivative · entry 3 Seim Robin Gene · CIK 0001351911 · President, Global A & M A 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,386 F3 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2019 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2019 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:46 UTC |
Seim Robin GenePresident, Global A & M A
|
GrantCommon Stock | 11,525 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-001771 · edgar.xml · nonDerivative · entry 2 Seim Robin Gene · CIK 0001351911 · President, Global A & M A 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,319 F1 · shares: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:46 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
GrantStock Option (Right to Buy) · Derivative | 27,072 | $0.00 Strike: $44.25 | $0.00 |
DisclosureSEC source: 0001179110-18-001770 · edgar.xml · derivative · entry 4 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,072 Underlying: Common Stock · 27,072 shares Expires 2028-02-06 F2 · shares: Shares shall vest ratably over 48 month period, with a year cliff. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:46 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
GrantCommon Stock | 6,918 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-001770 · edgar.xml · nonDerivative · entry 3 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,344 F3 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2019 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2019 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:46 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
GrantCommon Stock | 6,102 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-001770 · edgar.xml · nonDerivative · entry 2 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,426 F1 · shares: RSU: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:46 UTC |
Kuipers Peter J.Executive V P& CFO
|
GrantStock Option (Right to Buy) · Derivative | 45,120 | $0.00 Strike: $44.25 | $0.00 |
DisclosureSEC source: 0001179110-18-001769 · edgar.xml · derivative · entry 4 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,120 Underlying: Common Stock · 45,120 shares Expires 2028-02-06 F2 · shares: Shares shall vest ratably over 48 month period, with a year cliff. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:46 UTC |
Kuipers Peter J.Executive V P& CFO
|
GrantCommon Stock | 11,530 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-001769 · edgar.xml · nonDerivative · entry 3 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,236 F3 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2019 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2019 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:46 UTC |
Kuipers Peter J.Executive V P& CFO
|
GrantCommon Stock | 10,169 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-001769 · edgar.xml · nonDerivative · entry 2 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,706 F1 · shares: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:45 UTC |
Taborga Jorge R.EVP, Global R & D
|
GrantStock Option (right to Buy) · Derivative | 27,072 | $0.00 Strike: $44.25 | $0.00 |
DisclosureSEC source: 0001179110-18-001768 · edgar.xml · derivative · entry 4 Taborga Jorge R. · CIK 0001571822 · EVP, Global R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,072 Underlying: Common Stock · 27,072 shares Expires 2028-02-06 F2 · shares: Shares shall vest ratably over 48 month period, with a year cliff. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:45 UTC |
Taborga Jorge R.EVP, Global R & D
|
GrantCommon Stock | 6,918 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-001768 · edgar.xml · nonDerivative · entry 3 Taborga Jorge R. · CIK 0001571822 · EVP, Global R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,612 F3 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2019 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2019 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:45 UTC |
Taborga Jorge R.EVP, Global R & D
|
GrantCommon Stock | 6,102 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-001768 · edgar.xml · nonDerivative · entry 2 Taborga Jorge R. · CIK 0001571822 · EVP, Global R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,694 F1 · shares: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years. Read SEC document |
| December 18, 2017 Filed Dec 18, 2017 21:29 UTC |
Kuipers Peter J.Executive V.P. CFO
|
SaleCommon Stock | 1,926 | $51.69 | $99,559.37 |
DisclosureSEC source: 0001179110-17-015496 · edgar.xml · nonDerivative · entry 4 Kuipers Peter J. · CIK 0001651691 · Executive V.P. CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,537 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F3 · price: The price reported in Column 4 is the average price of $51.6923. The shares sold between $51.50 to $51.90. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 18, 2017 Filed May 2, 2019 00:11 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
SaleCommon Stock | 35,879 | $51.24 | $1,838,508.13 |
DisclosureSEC source: 0001179110-19-005372 · edgar.xml · nonDerivative · entry 4 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · In Trust with Wife Disclosed balance after: 280,613 F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F14 · shares: The price reported in Column 4 is the average price of $51.2419. The sold price range between $51.2361 to $51.9333. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This transaction is being reported late due to an inadvertent administrative error. F14 · price: The price reported in Column 4 is the average price of $51.2419. The sold price range between $51.2361 to $51.9333. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This transaction is being reported late due to an inadvertent administrative error. F1 · ownership.nature: Shares held in trust with Mr. Lipps' wife. Read SEC document |
| December 15, 2017 Filed Dec 18, 2017 21:29 UTC |
Kuipers Peter J.Executive V.P. CFO
|
Tax withholdingCommon Stock | 1,611 | $51.75 | $83,369.25 |
DisclosureSEC source: 0001179110-17-015496 · edgar.xml · nonDerivative · entry 3 Kuipers Peter J. · CIK 0001651691 · Executive V.P. CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,463 F1 · price: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2017 Filed Dec 18, 2017 21:29 UTC |
Kuipers Peter J.Executive V.P. CFO
|
Tax withholdingCommon Stock | 470 | $51.75 | $24,322.50 |
DisclosureSEC source: 0001179110-17-015496 · edgar.xml · nonDerivative · entry 2 Kuipers Peter J. · CIK 0001651691 · Executive V.P. CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,074 F1 · price: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2017 Filed Dec 18, 2017 21:28 UTC |
JOHNSTON DAN SEVP-Chief Legal & Admin Off
|
Tax withholdingCommon Stock | 975 | $51.75 | $50,456.25 |
DisclosureSEC source: 0001179110-17-015494 · edgar.xml · nonDerivative · entry 3 JOHNSTON DAN S · CIK 0001271802 · EVP-Chief Legal & Admin Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,324 F1 · price: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2017 Filed Dec 18, 2017 21:28 UTC |
JOHNSTON DAN SEVP-Chief Legal & Admin Off
|
Tax withholdingCommon Stock | 1,909 | $51.75 | $98,790.75 |
DisclosureSEC source: 0001179110-17-015494 · edgar.xml · nonDerivative · entry 2 JOHNSTON DAN S · CIK 0001271802 · EVP-Chief Legal & Admin Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,299 F1 · price: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2017 Filed Dec 18, 2017 21:28 UTC |
DREW J CHRISTOPHERExe VP, Sales & Marketing
|
Tax withholdingCommon Stock | 1,577 | $51.75 | $81,609.75 |
DisclosureSEC source: 0001179110-17-015492 · edgar.xml · nonDerivative · entry 4 DREW J CHRISTOPHER · CIK 0001271482 · Exe VP, Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,370 F1 · price: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2017 Filed Dec 18, 2017 21:28 UTC |
DREW J CHRISTOPHERExe VP, Sales & Marketing
|
Tax withholdingCommon Stock | 2,879 | $51.75 | $148,988.25 |
DisclosureSEC source: 0001179110-17-015492 · edgar.xml · nonDerivative · entry 3 DREW J CHRISTOPHER · CIK 0001271482 · Exe VP, Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,947 F1 · price: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2017 Filed Dec 18, 2017 21:28 UTC |
Taborga Jorge R.Executive VP. Engineering
|
Tax withholdingCommon Stock | 739 | $51.75 | $38,243.25 |
DisclosureSEC source: 0001179110-17-015489 · edgar.xml · nonDerivative · entry 3 Taborga Jorge R. · CIK 0001571822 · Executive VP. Engineering 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,592 F1 · price: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2017 Filed Dec 18, 2017 21:28 UTC |
Taborga Jorge R.Executive VP. Engineering
|
Tax withholdingCommon Stock | 1,387 | $51.75 | $71,777.25 |
DisclosureSEC source: 0001179110-17-015489 · edgar.xml · nonDerivative · entry 2 Taborga Jorge R. · CIK 0001571822 · Executive VP. Engineering 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,331 F1 · price: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2017 Filed Dec 18, 2017 21:24 UTC |
Seim Robin GeneEVP, Global A & M Adherence
|
Tax withholdingCommon Stock | 2,223 | $51.75 | $115,040.25 |
DisclosureSEC source: 0001179110-17-015482 · edgar.xml · nonDerivative · entry 3 Seim Robin Gene · CIK 0001351911 · EVP, Global A & M Adherence 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,794 F1 · price: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.